### Edgar Filing: GILEAD SCIENCES INC - Form 4

GILEAD S Form 4 May 03, 20	CIENCES INC										
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMPLESION									OMB APPROVAL		
Check t	his box								Number: Expires:	3235-0287 January 31,	
if no lor subject Section Form 4	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF16.SECURITIES							Estimated a burden hour response	•		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> MARTIN JOHN C			2. Issuer Name <b>and</b> Ticker or Trading Symbol GILEAD SCIENCES INC [GILD]					5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (	(Middle) 3. Date of Earliest Transaction				(Check X Director	ck all applicable)				
GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE			05/01/2017					X_Officer (give titleOther (specify below) below) Executive Chairman			
			Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
FOSTER C						Form filed by More than One Reporting Person					
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Secur	ities Acqu	iired, Disposed of,	or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deema Execution any (Month/Da	Date, if Transactionor Disposed of (D) Code (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
Common	05/01/2017			Code V	Amount	(D)	Price	(Instr. 3 and 4)	D		
Stock	05/01/2017			M <u>(1)</u>	73,333	A		5 3,199,969	D		
Common Stock	05/01/2017			S	73,333	D	\$ 68.3107 ( <u>3)</u>	7 3,126,636	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Edgar Filing: GILEAD SCIENCES INC - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	<ul> <li>5. Number of actionDerivative</li> <li>8. Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)</li> <li>6. Date Exercisable Expiration Date (Month/Day/Year)</li> <li>6. Date Exercisable Expiration Date (D) (Instr. 3, 4, and 5)</li> </ul>		ate	7. Title and A Underlying S (Instr. 3 and	Securiti	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amou or Numl of Sh
Non-qualified Stock Option (Right to Buy)	\$ 21.575	05/01/2017		M <u>(1)</u>		73,333	(2)	01/30/2018	Common Stock	73,3

# **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships						
1	Director	10% Owner	Officer	Other			
MARTIN JOHN C GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY, CA 94404	Х		Executive Chairman				
Signatures							

### /s/ Jason Okazaki by Power of Attorney for John C. Martin <u>\*\*</u>Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- (2) The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- (3) Sale prices reported for the transactions reported here range from \$68.07 to \$68.78. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.